Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMBAIH)

• Drug Name: NXN-188 Drug Info
• Synonyms: 6634-56-6; 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid; NSC51920; AC1Q5VTF; AC1L6AFP; CTK5C4317; ZINC4721635; NSC-51920; AKOS030583716; KB-274877

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 242911
  CAS Number: CAS 6634-56-6
  TTD Drug ID: DMMBAIH

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
Eletriptan	DMW649X	Migraine	8A80	Approved	[5]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[5]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[5]
Naratriptan	DMO50U2	Migraine	8A80	Approved	[6]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[5]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[7]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[8]
Alniditan	DMFE3CT	Migraine	8A80	Discontinued in Phase 3	[9]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[10]
Eletriptan	DMW649X	Migraine	8A80	Approved	[5]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[5]
Sumatriptan	DMVYXR8	Migraine	8A80	Approved	[11]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[12]
Almogran	DM7I64Z	Migraine	8A80	Approved	[13]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[14]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[15]
TGBA01AD	DMJ2FTU	Mood disorder	6A60-6E23	Phase 2	[16]

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[17]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[18]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[19]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[19]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[19]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[20]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[19]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[19]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[21]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	DMUCJA6	Discovery agent	N.A.	Investigative	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Modulator	[2]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Modulator	[2]
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.
• [2] Company report (NeurAxon)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [7] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [8] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [9] Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
• [10] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [11] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [12] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [13] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [14] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Company report (Fabrekramer)
• [17] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [18] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [19] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
• [22] Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.